Skip to main content
. 2012 Jun 8;18(1):1086–1095. doi: 10.2119/molmed.2012.00033

Figure 3.

Figure 3

zVAD-fmk reverts R-roscovitine–induced reduction in PMNs and protein content of BAL fluid. Lung inflammation was induced by intranasal instillation of 100 μg LTA. Simultaneously, 70 mg/kg R-roscovitine, 70 mg/kg R-roscovitine combined with 5 mg/kg zVAD-fmk or vehicle (10% DMSO) was administered intraperitoneally. After 24 h, animals were sacrificed and samples were taken. Cellular content obtained from pelleted BAL fluid was lysed and cleaved caspase-3 levels were determined by Western blot; representative Western blot is shown (A). The bar graph expresses data as fold-change of vehicle. Cell differentiations (B) and PMN counts (C) and total protein (D) were measured in BAL fluid. Annexin V binding was assessed in BAL-obtained cells. (E) The scatter plot of side scatter and Ly-6G staining (left) and scatter plots of 7-AAD + annexin V staining for vehicle, R-roscovitine and R-roscovitine + zVAD-fmk treatment (right graphs). (F) Bars show percentage-positive PMNs for the staining indicated. Data are expressed as mean ± SEM; n = 4–8. *P < 0.05, #P < 0.05 versus vehicle control.